Medexus Pharmaceuticals Inc MEDXF

Primary Symbol: T.MDP

Healthcare

Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.

TSX:MDP - Post by User

Medexus Pharmaceuticals Inc > Ebitda Sector Multiple

<< Previous

Bullboard Posts

Next >>

Comment by nozzpackon Aug 09, 2023 6:21pm

91 Views

Post# 35580601

RE:Ebitda Sector Multiple

Ebitda of $6,6 million US in Q1 which is about $8.2 million in cad.

Annualized, Thats about $33 million CAD

Ebitda in this sector has a muktiple of 13 times ;( see my recent post ) which computes to a fare market cap of about $410 million cad or about $ 19 per share.

This story just keeps getting better with each and every reporting quarter..

<< Previous

Bullboard Posts

Next >>

2024, a breakthrough year for silver